This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

OXiGENE Announces Presentation Of Encouraging OXi4503 Preclinical And Clinical Data In Acute Myelogenous Leukemia At American Society Of Hematology Meeting

SOUTH SAN FRANCISCO, Calif., Dec. 10, 2012 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced today that investigators at the University of Florida presented encouraging clinical data using OXiGENE's vascular disrupting agent (VDA), OXi4503, in patients with acute myelogenous leukemia (AML) at the 2012 annual meeting of the American Society of Hematology in Atlanta, Georgia. The data showed responses and a manageable safety profile in this first-in-man trial of a VDA in AML.

The clinical data were presented as an online abstract from an investigator-sponsored Phase 1 study of OXi4503, which is supported in part by the Leukemia & Lymphoma Society, for the treatment of patients with AML or myelodysplastic syndrome (MDS). The ongoing open-label, dose-escalating study is evaluating the safety profile, maximum tolerated dose (MTD) and biologic activity of OXi4503. Results were presented on 5 patients with refractory AML enrolled between May, 2011 and August, 2012. The median number of prior therapies was 4 (range, 1-7). Two subjects were assigned to the 2.5 mg/m 2 dosing cohort, 2 received 3.75 mg/m 2 and 1 received 5 mg/m 2. None of these patients developed dose-limiting toxicities. Adverse events attributable to OXi4503 infusion included bone pain, fever, anemia and thrombocytopenia. Hypertension was manageable and plasma LDH and uric acid increased by at least two-fold within hours after OXi4503 infusions, suggesting leukemia cell destruction.

Overall response was 2/5 (40%), with 1 patient achieving a marrow complete remission (mCR) and 1 patient achieving a partial remission (PR). The median number of cycles was 1 (range 1-6). Three of 5 subjects discontinued the study due to AML progression and one due to pneumonia. One patient with AML treated with 5 mg/m 2 OXi4503 has received 6 months of treatment and continues to receive weekly infusions.

To further elucidate the mechanism of AML regression by combretastatins, investigators at the University of Florida also presented preclinical data in a poster presentation titled "Vascular Disrupting Combretastatins Impair Bone Marrow Endothelial Cells by Depolymerizing the Microtubule Cytoskeleton." In this study, bone marrow endothelial cells (BMECs) from both healthy subjects and patients with AML were treated with various doses of the combretastatins OXi4503 and ZYBRESTAT® for 24 and 48 hours. The results showed that both combretastatins impaired BMECs migration and function compared to untreated control. In addition, there was a distinct degradation of microtubule cytoskeleton in BMECs treated with the two combretastatins. AML cells co-cultured with BMECs treated with the two combretastatins showed a lower survival rate than AML cells alone. Conclusions were that combretastatins directly impair BMEC function and eliminate BMEC protection of AML cells, and the dual targeting of combretastatins on BMECs and AML cells leads to enhanced AML regression.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $94.27 -0.76%
FB $101.00 1.47%
GOOG $684.12 0.89%
TSLA $143.67 -3.09%
YHOO $27.10 1.04%


Chart of I:DJI
DOW 15,914.74 -99.64 -0.62%
S&P 500 1,851.86 -0.35 -0.02%
NASDAQ 4,283.5920 +14.8290 0.35%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs